Clinical Significance of 99mTc-MIBI Breast Imaging in the Diagnosis of Early Breast Cancer

Ren, Changcai; Shaojin, Jin; Zhou, Qiang; Zhu, Huilian; Wang, Hongying; Liang, Chao

doi:10.1016/s1015-9584(09)60159-7

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These prior attempts to detect changes in breast tissue 9,10 have been limited by the ability to change blood flow and subsequent isotope uptake into mitochondrial tissue. This limitation was overcome with the development of breast-enhanced scintigraphy test (BEST) imaging, [11][12][13] which takes advantage of evaluating both mitochondrial activity and changes in blood flow.…”

mentioning

confidence: 99%

Are there differences in Breast Tissue as a Result of Hormone Replacement Therapy? Can BEST Imaging Distinguish these Differences?

Fleming¹

2003

Integr Cancer Ther

View full text Add to dashboard Cite

Although it has been speculated that estrogen therapy may promote changes in breast tissue that could lead to cancer, no information exists as to differences in breast tissue for women who do and do not take hormone replacement (HRT) therapy. This study seeks to determine if there are differences in the tissue of women taking HRT in contrast to those who do not and if these differences are apparent in cases of breast cancer, cellular atypia, fibrocystic (FCD) disease and normal breasts. A total of 327 non-pregnant, non-lactating, pre-menopausal women were enrolled in the study, including 139 women who were actively taking HRT and 188 women who never had taken HRT. Using breast enhanced scintigraphy test (BEST) imaging, differentiation of breast tissue was determined. The groups were then analyzed to determine the effect of hormone therapy within each category of breast tissue. Differentiation between normal, FCD, cellular atypia, and breast cancer represent statistically significant differences (p.001) in metabolic activity and vascularity as demonstrated by differences in both average count activity (ACA) and maximal count activity (MCA). The distinction between cellular atypia and infiltrating breast cancer was statistically (p.05) different when looking at the maximal activity. Normal breast tissue and breasts with FCD appear more homogenous with no statistical differences in variability in breast tissue. Tissue variability is statistically greater when localized processes, such as cellular atypia and breast cancer, are present. Differentiation of cellular metabolic activity in breast tissue can be statistically determined when looking at the average and maximal metabolic activity. The final distinction between cellular atypia and cancer occurs when a focal region of breast tissue becomes metabolically more active than the surrounding breast tissue as shown by statistical increases in MCA. These findings are confirmed by the increased metabolic variability seen in regions of cellular atypia and cancer compared with the homogenous metabolic activity present in normal and fibrocystic breasts.

show abstract

mentioning

confidence: 99%

Are there differences in Breast Tissue as a Result of Hormone Replacement Therapy? Can BEST Imaging Distinguish these Differences?

Fleming¹

2003

Integr Cancer Ther

View full text Add to dashboard Cite

show abstract

“…В настоящее время появились новые методические подходы к биопсии сигнальных лимфатических узлов (БСЛУ), которые могут иметь существенное значение для повышения информативности этого исследования. хирургическое лечение больных с радиоизотопной детекцией и интраоперационным гистологическим исследованием сигнальных лимфатических узлов, как компонент органосохраняющего или функционально щадящего лечения, создает возможность более точного стадирования заболевания [13,16].…”

unclassified

Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the N.N. Petrov Research Institute of Oncology

Krivorotko¹,

Зернов²,

Палтуев³

et al. 2017

Problems in oncology

View full text Add to dashboard Cite

The aim of the study was to evaluate a 3-year distant treatment outcomes of patients with early breast cancer who had undergone sentinel lymph node biopsy. Methods. A total of 681 patients with early cT1-2N0M0 breast cancer treated in the N.N. Petrov research institute of oncology form 2012 till 2016 were retrospectively enrolled in the study. Radioisotopes were used to identify sentinel nodes. In case a macrometastatic lesion was found (>2mm) ALND was performed. Subsequent adequate systemic treatment and radiotherapy were administered in accordance with the pTNM status, biologic subtype and age. Results. A 3-year overall survival equaled 99.3% (SE 0.4%), recurrence-free survival was 99.2% (SE 0.4%). Survival of patients without nodal involvement reached 100%, whereas for patients with metastatic nodes it was 97.4% (SE 1.8%). The threshold for the number of the affected nodes significantly influencing survival equaled 1 (р=0,0187). Overall survival of patients with 0 to 1 positive lymph nodes was 99.7% (SE 0.3%), with more than 1 node involved - 95.7% (SE 0.3%) (р=0,00444). Conclusion. Overall 3-year survival of patients with early breast cancer approaches 100%. Sentinel lymph node biopsy allows avoiding unnecessary and traumatizing axillary dissection and improves the quality of life.

show abstract

Clinical Significance of 99mTc-MIBI Breast Imaging in the Diagnosis of Early Breast Cancer

Abstract: 99mTc-MIBI imaging had high sensitivity and accuracy in the diagnosis of breast cancer, as well as in the differentiation between benign and malignant breast lesions. It could provide reliable information in confirming the diagnosis in patients with clinically suspected breast cancer.

Cited by 2 publications

References 3 publications

Are there differences in Breast Tissue as a Result of Hormone Replacement Therapy? Can BEST Imaging Distinguish these Differences?

Are there differences in Breast Tissue as a Result of Hormone Replacement Therapy? Can BEST Imaging Distinguish these Differences?

Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the N.N. Petrov Research Institute of Oncology

Contact Info

Product

Resources

About